Unicycive Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $568 | $0 |
Gross Profit | -138 | -135 | 284 | -123 |
EBITDA | -6,296 | -7,989 | -21,371 | -3,958 |
EBIT | -6,434 | -8,124 | -21,505 | -4,081 |
Net Income | -6,447 | 570 | -21,525 | -4,096 |
Net Change In Cash | 0 | 0 | 568 | 0 |
Free Cash Flow | -8,426 | -8,919 | -6,570 | -9,276 |
Cash | 22,327 | 19,769 | 26,142 | 32,347 |
Basic Shares | 12,302 | 12,383 | 6,698 | 8,894 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $675 | $951 | $0 |
Gross Profit | -428 | 675 | 951 | -1 |
EBITDA | -36,230 | -30,178 | -17,891 | -8,964 |
EBIT | -36,658 | -30,462 | -18,052 | -8,977 |
Net Income | -36,729 | -30,544 | -18,064 | -10,632 |
Net Change In Cash | 0 | 675 | 951 | 0 |
Free Cash Flow | -28,647 | -18,295 | -15,653 | -5,796 |
Cash | 26,142 | 9,701 | 455 | 16,579 |
Basic Shares | 6,698 | 2,453 | 1,505 | 1,499 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.50 |
2025-03-31 | -$0.50 |
2024-12-31 | $0.25 |
2024-09-30 | -$0.05 |
